Segment Information

9 Months Ended

Sep. 30, 2013

Segment Reporting [Abstract]

Segment Reporting Disclosure [Text Block]

SEGMENT INFORMATION

We operate in one business segment, which primarily focuses on the discovery, development and commercialization of innovative medicines in areas of unmet medical need. All products are included in one segment, because the majority of our products have similar economic and other characteristics, including the nature of the products and production processes, type of customers, distribution methods and regulatory environment.

Product sales consist of the following (in thousands):

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2013		2012		2013		2012
Antiviral products:
Atripla	$	899,669	$	865,378	$	2,714,850	$	2,656,997
Truvada	813,652		804,190		2,321,673		2,348,386
Viread	231,555		214,909		692,075		622,016
Complera/Eviplera	210,736		99,297		547,608		224,386
Stribild	143,953		17,511		335,495		17,511
Hepsera	20,316		27,319		68,195		82,807
Emtriva	6,846		7,229		20,156		21,819
Total antiviral products	2,326,727		2,035,833		6,700,052		5,973,922
Letairis	135,072		105,054		381,436		293,976
Ranexa	115,815		95,066		318,698		273,822
AmBisome	97,812		87,448		258,224		255,865
Other products	34,226		34,577		102,095		89,975
Total product sales	$	2,709,652	$	2,357,978	$	7,760,505	$	6,887,560

The following table summarizes revenues from each of our customers who individually accounted for 10% or more of our total revenues (as a percentage of total revenues):

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2013		2012		2013		2012
Cardinal Health, Inc.	16	%	18	%	18	%	19	%
McKesson Corp.	16	%	16	%	16	%	16	%
AmerisourceBergen Corp.	15	%	11	%	13	%	11	%